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Alternative, non-electrochemistry-based technologies for continuous glucose monitoring are needed
for eventual use in diabetes mellitus. As part of a programme investigating fluorescent glucose sensors,
we have developed fibre-optic biosensors using glucose/galactose binding protein (GBP) labelled with
the environmentally sensitive fluorophore, Badan. GBP–Badan was attached via an oligohistidine-tag
to the surface of Ni–nitrilotriacetic acid (NTA)-functionalized agarose or polystyrene beads.
Fluorescence lifetime increased in response to glucose, observed by fluorescence lifetime imaging
microscopy of the GBP–Badan-beads. Either GBP–Badan agarose or polystyrene beads were loaded
into a porous chamber at the end of a multimode optical fibre. Fluorescence lifetime responses were
recorded using pulsed laser excitation, high speed photodiode detection and time-correlated single-
photon counting. The maximal response was at 100 mM glucose with an apparent Kd of 13 mM
(agarose) and 20 mM (polystyrene), and good working-day stability was demonstrated. We conclude
that fluorescence lifetime fibre-optic glucose sensors based onGBP–Badan are suitable for development
as clinical glucose monitors.
Introduction
The current sensors for continuous glucose monitoring in dia-
betes which are used in clinical practice are subcutaneously
implanted needle-type enzyme electrodes or microdialysis
probes. Both are based on glucose oxidase and either the elec-
trochemical detection of hydrogen peroxide produced by the
oxidation of glucose or ‘wired’ electron transfer from the
enzyme to an underlying electrode.1 Such glucose sensors are
making a useful contribution to the management of diabetic
patients2 but have suboptimal accuracy and performance, due
to impaired responses in vivo and signal drift. This necessitates
frequent calibration against capillary blood glucose samples.3
The possible reasons for this inaccuracy include interfering
electroactive substances in the tissues, coating of the sensor by
protein and cells and changes in blood flow that alter oxygen
access.3 Alternative sensing technologies not based on electro-
chemistry or glucose oxidase are therefore being actively
investigated.
Fluorescence-based glucose sensing is being researched by
several groups4,5 and has the advantages of sensitivity and lack of
electrochemical interference. Moreover, measurement of fluo-
rescence decay lifetime, as opposed to intensity, has special
potential for in vivo sensing6,7 because it is relatively independent
of light scattering in the tissues, signal amplitude fluctuations and
fluorophore concentration—thus coating of an implanted sensor,
which may reduce fluorescence intensity, will leave the lifetime
unaltered.
Fluorescence glucose sensors may be envisaged as totally
implanted,8 formulated as microcapsules for impregnation in the
skin as a ‘smart tattoo’,9–12 as nanocapsules (pebbles or poly-
mersomes) for intracellular sensing,13,14 as an intravenous
catheter,15 and as a fibre-optic probe.16–19 Fibre-optic glucose
sensors have the attraction of ease of implantation into and
removal from the subcutaneous tissue, containment of the
sensing element, and communication between the tissues and
instrumentation outside the body via a waveguide which is
minimally invasive, electrical isolated and generally biocom-
patible.18,20
Several receptors for glucose have been investigated for fluo-
rescence-based glucose sensing4 including boronic acid deriva-
tives,4 concanavalin A4,17,19,21 and other lectins,8 glucose
oxidase4,13,16 and bacterial glucose/galactose-binding protein
(GBP).12,22–30 GBP undergoes a large change in molecular
conformation on binding glucose, which can be detected by
either fluorescence resonance energy transfer or by labelling with
an environmentally sensitive fluorophore.12,29,30 The binding
constant for native GBP is in the micromolar range and therefore
unsuitable for clinical glucose monitoring, but we recently
reported30 the synthesis of a new triple mutant of GBP with a Kd
of 11 mM and operating range of up to 100 mM glucose, which
we labelled with the environmentally sensitive fluorophore,
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Badan, at a position near the binding site. Addition of glucose
produced a large increase in both fluorescence intensity and
lifetime. The responses to glucose of the GBP–Badan were the
same in serum and buffer.30
We now report the use of the high-Kd mutant of GBP (labelled
with Badan) in a fibre-optic glucose sensor and proof-of-concept
testing in vitro. A significant barrier to the use of GBP in such
devices is immobilization of the protein on the probe without
impairment of the conformation-based sensing. Our preliminary
research (M. Ferla and J. C. Pickup, unpublished studies) indi-
cated that several commonly used immobilization strategies such
as entrapment in silica sol–gels and covalent linking to hydrogels
can impair glucose sensing. We therefore investigated and report
here the use of binding of GBP–Badan to Ni–nitrilotriacetic acid
(NTA)-functionalised agarose or polystyrene beads, via an
engineered oligohistidine tag on the GBP, and the employment
of this immobilized protein in a fibre-optic glucose sensor.
The technology for fluorescence lifetime measurement is now
well-established.7 Although fluorescence lifetime is used less in
sensors than in spectroscopy and microscopy, optical fibre-
coupled fluorescence lifetime measurements have been proven
for some time.31 Indeed the proof of principle is already estab-
lished for lab-on-a-chip distributed multiplexed sensor networks
whereby several metabolites could be monitored simultaneously
for point-of-care applications.32
Here we have used time domain pulsed optical excitation, but
the same glucose sensor would be equally compatible with
frequency-domain phase-modulation methods.6
Results and discussion
Ni–NTA agarose beads for binding GBP–Badan
Ni–NTA functionalised agarose beads were linked to His-tagged
GBP–Badan as the glucose receptor and imaged using epi-fluo-
rescence microscopy. The beads, in glucose-free phosphate-
buffered saline (PBS), displayed high fluorescence intensity due
to the large amount of protein bound to the Ni–NTA agarose
(Fig. 1a).
Two fixed fluorescence lifetimes for GBP–Badan linked to
agarose were generated from a global bi-exponential fit to the
data. These were found to be 2.7 and 0.9 ns, which from previous
work may be considered to correspond respectively to the
glucose-bound (closed) and unbound (open) configurations of
GBP–Badan.12 These lifetimes differ only slightly from previ-
ously measured values for GBP–Badan in solution, most likely
due to the immobilisation of the protein.
On addition of glucose, changes are observed in the fractional
intensity (Fi) of each lifetime (si). For a bi-exponential decay,
a mean lifetime (s) is derived from the following equation:
s ¼ F1s1 + F2s2 (1)
where
F1 + F2 ¼ 1 (2)
Fluorescence lifetime images in glucose-free buffer and satu-
rating (100 mM) glucose showed an increase in the mean lifetime
with addition of glucose (Fig. 1b and c).
This fluorescence response is similar to our previous work on
mutants of GBP labelled with Badan29,30 and studied in solution
and in vesicles, where an increase in fluorescence intensity and
lifetime was found with glucose addition. The present studies
confirm that the response to glucose was retained when GBP–
Badan was bound to the agarose beads.
The main use of Ni–NTA bound to a solid matrix such as
agarose beads to date has been in ‘immobilized metal-affinity
chromatography’, i.e. the purification of recombinant proteins,
where a genetically engineered polyhistidine tag on one terminus
of the protein binds to the support via a metal–histidine inter-
action.33 NTA has four chelating sites, allowing two nickel
coordination sites free to bind to the protein. To the best of our
knowledge, Ni–NTA–His tag binding has not previously been
used to immobilize protein at fibre-optic biosensors.
Ni–NTA functionalized agarose beads for use in a fibre-optic
glucose sensor
The dose–response curve for the GBP–Badan–agarose beads
incorporated in a fibre-optic glucose sensor is shown in Fig. 2.
The percentage change in the mean fluorescence lifetime is
Fig. 1 Ni–NTA agarose beads with bound GBP–Badan. (a) Epi-fluorescence intensity image (lex ¼ 400 nm and lem ¼ 550 nm). Mean fluorescence
lifetime images of beads in 10 mM PBS and (b) zero glucose, and (c) saturated (100 mM) glucose.






























































plotted, corresponding to a change of 0.6 ns over the measured
glucose range. The apparent Kd was estimated at 13 mM from
a hyperbolic fit to the data, and is thus suitable for glucose
measurement over the physiological and pathophysiological
range. This compares with our previously reported Kd of 11 mM
for this mutant of GBP labelled with Badan but when studied in
solution.30 However, the apparent Kd of the sensor represents the
operating range of the device, rather than the true binding
constant of the GBP–Badan.
The response time from 0 to 100 mM glucose concentration
was 10 min (Fig. 3), with a reversible response on removal of
glucose, although the ‘off’ response time increased to approxi-
mately one hour.
Fibre-optic glucose sensor with GBP–Badan bound to Ni–NTA
functionalized polystyrene beads
Individual lifetime values of 2.7 ns and 0.8 ns were generated by
the bi-exponential fit for GBP–Badan bound to polystyrene
beads, similar to the lifetime values for agarose-bound GBP–
Badan.
The dose–response curve for the fibre-optic glucose sensor
based on GBP–Badan linked to Ni–NTA polystyrene beads also
showed an increase in mean fluorescence lifetime on addition of
glucose, though with a smaller maximal increase corresponding
to 0.25 ns (Fig. 2). The Kd was estimated at 20 mM from
a hyperbolic fit to the data.
The response time of the polystyrene bead-based sensor from 5
to 20 mM glucose was approximately 10 min, with an ‘off’
response time similar to that of the agarose sensor. There was
good stability over the course of a working day (Fig. 4). Fluo-
rescence lifetime is considered to be independent of photo-
bleaching. As the sensor response was found to be stable
throughout the course of the day in our study, it can be
concluded that any photo-bleaching that occurred had no effect
on the signal, and the theoretical advantage of lifetime-based
sensing over intensity-based sensing is confirmed.
Experimental
Reagents and materials
PBS (10 mM, pH 7.4) was used unless otherwise stated. The triple
mutant of GBP (H152C/A213R/L238S) was synthesized and
labelled with the environmentally sensitive fluorophore, Badan
(Invitrogen, Paisley, UK), covalently linked at position 152C, as
previously described.30 The protein was engineered with a hexa-
histidine tag at the C-terminus, which enabled binding to the Ni–
NTA moiety. Ni–NTA agarose beads (100–200 mm diameter)
were obtained from Qiagen (Crawley, UK). Ni–NTA poly-
styrene beads (100 mm diameter) were obtained from Micromod
(Rostock, Germany). 0.48 NA, hard polymer-clad multimode
optical fibre (high OH, 1000 mm core) was from Thorlabs (Ely,
UK). Hydrophilic nylon mesh (20 mm pore size) was obtained
from Spectrum Labs (Rancho Dominguez, CA, USA).
Attachment of GBP–Badan to agarose or polystyrene beads
5 ml packed Ni–NTA agarose beads were washed three times in
PBS to remove ethanol and the supernatant removed. Beads were
Fig. 2 Percent change in mean fluorescence lifetime against glucose
concentration, for Ni–NTA agarose and Ni–NTA polystyrene-based
glucose sensors. Kd values were estimated by fitting with a hyperbolic
dose–response function.
Fig. 3 Time course for the agarose bead fibre-optic sensor, for addition
and removal of saturating glucose (expressed as fraction of the maximal
response).
Fig. 4 Stability of the Ni–NTA polystyrene bead-based fibre-optic
glucose sensor over the course of a working day. The scale on the y-axis is
reflective of the range of the sensor, from the minimum to maximum
lifetime.






























































then incubated with 20 ml of GBP–Badan (50 mM) in PBS for 4
hours on a roller at 25 C. The beads were washed again and
finally re-suspended in 10 ml PBS. Ni–NTA functionalised
polystyrene beads (20 ml of 50 mg ml1 solution) were labelled
with GBP–Badan in a similar fashion.
Construction of fibre-optic glucose sensor
The surface of 1000 mm core multimode fibre (Thorlabs) was
prepared by controlled breaking using a diamond scribe. A 2 mm
long chamber for the glucose-sensing agarose or polystyrene
beads was formed using a section of 1.5 mm diameter glass
tubing and secured with epoxy resin at the tip of the fibre optic,
as illustrated in Fig. 5. The beads were placed in the chamber and
a wetted 3 mm circle of nylon mesh was applied to the end of the
fibre, covering the chamber, and fixed in place using a rubber O-
ring.
Fluorescence lifetime measurement with fibre-optic glucose
sensor
The experimental set-up for fluorescence excitation and
recording is shown in Fig. 6. Excitation was provided by
a supercontinuum, femto second pulsed laser (sc400, Fianium,
Southampton, UK) filtered to 417  30 nm. Emission was
filtered and collected at 542  25 nm using a high speed photo-
multiplier tube (PMT) (PMH-100, Becker and Hickl, Berlin,
Germany). The signal from the PMT was processed using a time-
correlated single-photon counting (TCSPC) card (spc830, Becker
and Hickl). Data were analysed using TRI2 software, courtesy of
Paul Barber, Grey Cancer Institute, Oxford and as previously
described.12 Mean lifetimes were calculated from the fractional
intensities, generated by a bi-exponential fit as previously
described.12
Fluorescence intensity and lifetime imaging microscopy
GBP–Badan bound to agarose or polystyrene beads was imaged
using an upright 90i fluorescence microscope (Nikon, Tokyo,
Japan) and custom-built fluorescence lifetime imaging instru-
mentation, as previously described.12
Glucose sensor responses
For in vitro testing, the fibre-optic glucose sensor was immersed
in 100 ml PBS in a jacketed glass organ bath, with constant
stirring and temperature maintained at 26 C using a thermo-
statically controlled water bath (GD120, Grant Instruments,
Shepreth, UK). Aliquots of 1 M stock glucose solution were
added sequentially to alter the glucose concentration.
Fig. 5 Diagram of the terminus of the fibre-optic glucose sensor con-
taining GBP–Badan labelled beads.
Fig. 6 Diagram of the experimental set up. A femto-second pulsed,
supercontinuum laser was filtered to 417 nm and imaged at the terminus
of a 1000 mmmulti-mode fibre. Fluorescence from the sensor terminus of
the fibre was collected, filtered and laser excitation removed using a 540
nm band pass filter and 495 nm razor edge filter. Fluorescent emission
was acquired by a high-speed PMT and processed by time-correlated
single-photon counting (TCSPC) electronics.






























































For stability experiments, the optical fibre was immersed in 20
mM glucose solution in an organ bath as before, and maintained
at 25.5–25.9 C with stirring.
Conclusion
These studies demonstrate proof-of-concept for a fibre-optic
glucose sensor using GBP–Badan and measuring fluorescence
lifetime changes. The sensor response was best conserved using
Ni–NTA functionalised agarose beads as an immobilisation
strategy. Ni–NTA functionalised polystyrene beads result in
a slightly reduced response (percent change in fluorescence life-
time), possibly due to charge effects that alter the fluorescence of
the Badan.
Glucose responses of the immobilised sensor are reversible and
stable and would allow clinical measurements about every one
hour. Although this would be of significant clinical use,
decreasing the response time, particularly the ‘off’ response,
would be valuable for monitoring rapidly changing blood
glucose concentrations. One strategy for accomplishing this may
be miniaturization of the fibre-optic probe (which in any case will
be needed for in vivo use), since previous work by others has
shown much faster response times with highly miniaturized
fluorescence glucose optodes.16
The realistic clinical value of a glucose sensor based on our
system will depend on demonstration of in vivo reversibility,
biocompatibility and lack of interference, and for a wearable
device, a miniaturised fluorescence lifetime measurement system
must be developed. The most important interfering substance
which binds to GBP is galactose, but in the concentration present
in plasma, this is unlikely to be a major problem in clinical
studies. The sensor was characterised using a pulsed laser and
time-correlated single-photon counting, however, a less complex
and potentially wearable system for clinical use should be
achievable. Indeed optical fibre coupling to a single integrated
circuit comprising light emitting34 or laser diode excitation,
avalanche photodiode detection and data processing in either the
time or frequency domain is now possible.
We demonstrate for the first time here that Ni–NTA linked to
solid supports such as agarose can be used to immobilize GBP
for use in a fibre-optic biosensor, and that this immobilization
does not impair the fluorescence response to glucose seen
previously in solution29,30 and in microcapsules.12 Other
recombinant proteins with an oligohistidine tag might also be
immobilized in this way at biosensor probes.
Following this proof-of-concept of a GBP-based fibre-optic
glucose sensor in vitro, the way is now clear for in vivo studies, say
with the probe implanted in the subcutaneous tissue, as
a preliminary to clinical exploitation as a continuous glucose
monitor.
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